Tolerogenic cell therapy for myasthenia gravis

Toleranzia is focused on developing innovative therapies that leverage the immune system's intrinsic capabilities to treat autoimmune orphan diseases. Their approach centers on the creation of tolerogens, which are disease-specific proteins designed to restore the immune system's tolerance to its own proteins that are mistakenly targeted in autoimmune conditions. This technology aims to induce immunological tolerance through repeated administration of these tailored substances, allowing the immune system to normalize its response without compromising its ability to defend against infections or cancer. 

The company's primary drug candidates include TOL2 for myasthenia gravis and TOL3 for ANCA vasculitis, both of which address significant unmet medical needs in the realm of rare diseases. Toleranzia's technology portfolio is characterized by its flexibility, as the tolerogens can be adapted for various autoimmune diseases, offering broad potential for new therapeutic developments. By specifically targeting the underlying causes of these diseases rather than merely alleviating symptoms, Toleranzia aims to provide long-acting or curative treatments that could significantly improve patient outcomes.

Sweden

Toleranzia develops protein-based antigen-specific immune tolerogens to cure patients with autoimmune diseases. The drugs have the potential to become the first long-acting or curative therapies that act specifically on the underlying cause of the autoimmune orphan disease for which they are being developed. The company has a lead project in myasthenia gravis as well as a second project in ANCA vasculitis. Toleranzia is listed on the Nasdaq First North Growth Market and backed by strongly committed renowned specialist investors.

Toleranzia

Company Details